Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AANAT | Q16613 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.67 |
| ▸ | MMP9 | P14780 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CDK4 | P11802 | 1/20 | 0.61 |
| ▸ | CCND1 | P24385 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761155 | 0.85 | MTNR1A (0.76) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL31114206 | 0.85 | MTNR1A (0.76) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL761552 | 0.84 | MEN1 (0.72) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL29399398 | 0.84 | MEN1 (0.72) | AANATMEN1KMT2ALMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL3826492 | 0.84 | MTNR1A (0.74) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL761481 | 0.84 | MTNR1A (0.88) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL5903804 | 0.83 | AANAT (0.77) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL10069200 | 0.83 | AANAT (0.77) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL7677886 | 0.83 | MEN1 (0.84) | AANATMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL14364790 | 0.83 | CDK4 (0.54) | AANATMEN1KMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968598-B1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | claimed |
| US-7713987-B2 | Pyrimidine-2,4-diamines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | claimed |
| EP-1968598-A1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2008088303-A1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | RIGEL, PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | MIDCAP FINANCIAL TRUST | 2007-06-07 | — | — | US | claimed |
| US-20070129360-A1 | N2-Chlorocarbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; kinase inhibitors; breast cancer; inhibiting signal transduction cascades in which Syk plays a role | PHAMIDIPATI SOMASEKHAR | 2007-06-07 | — | — | US | claimed |
| EP-1968598-B1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-7713987-B2 | Pyrimidine-2,4-diamines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1968598-A1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008088303-A1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | RIGEL, PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | MIDCAP FINANCIAL TRUST | 2007-06-07 | — | — | US | disclosed |
| US-20070129360-A1 | N2-Chlorocarbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; kinase inhibitors; breast cancer; inhibiting signal transduction cascades in which Syk plays a role | PHAMIDIPATI SOMASEKHAR | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129360-A1 | N2-Chlorocarbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; kinase inhibitors; breast cancer; inhibiting signal transduction cascades in which Syk plays a role | SYK, LYN, BTK | AANAT 1949/4885MEN1 3405/4885KMT2A 1181/4885 |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | DCK, DPYD, DTYMK | AANAT 1821/4885MEN1 2909/4885KMT2A 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.